Navigation Links
Novel method to reveal drug targets
Date:2/22/2008

Wellcome Trust Sanger Institute scientists have developed a new large-scale method to identify the interactions between proteins that are a major target for therapeutic intervention. The novel method can identify the weak, short-lived interactions that are characteristic of cell responses to cues from the environment or from within the body.

Cell surface proteins are targets for many drugs and are central to many processes of cell regulation, such as some cancer therapeutics, diabetes, and growth. The team hope the method will uncover many important interactions that are invisible to current detection methods.

Many proteins act as molecular switches, responding to signals and activating specific genes or specific cell processes. Using biochemical tricks to increase the chances of detecting the transient and weak, but potentially important, interactions, the scientists describe 17 new pairs of interactions in mammalian cells.

"If a genome is the code for life, interactions between proteins are the communications system - the internet of our bodies," Explains Dr Gavin Wright, Junior Investigator at the Wellcome Trust Sanger Institute. "The challenge we face is that current methods cannot efficiently detect interactions at the place where communication starts: the cell surface, nor can they reliably detect transient weak interactions.

"Our new method transforms the large-scale search for these important interactions."

Unlike DNA sequencing, where methods are common to all organisms, there has been no one approach that gives a global fit for all diverse protein-protein interactions. The new method, called AVEXIS, should be applicable to interactions at the cell surface in many organisms.

Drug targets are often proteins at the surface of the cell since they are easily accessible to drugs in contrast to proteins within our cells. Unfortunately, the current catalogue of known protein interactions is biased away from these proteins simply because there was no efficient method to examine them. Effectively, a swathe of clinically important targets is invisible to research.

"AVEXIS now allows us to scale the hunt for biologically and clinically important protein-protein interactions," continues Dr Wright. "These interactions are like Velcro - each hook can bind only weakly, but together, they can have a very strong effect. We increased the strength by gathering the proteins together, as in a small scrap of Velcro."

The team identified previously undescribed interactions in a class of proteins called the immunoglobulin superfamily: this group of proteins shares properties that are important to allow cells to respond to their environment, talk to one another and stick together. Using human proteins and zebrafish as a model, the Sanger Institute researchers looked at interactions between 110 proteins in this superfamily - a total of more than 6000 experiments.

They found 17 interactions that met stringent standards of reliability, several of which would last for less than 0.1 seconds in cells. For each, they looked to see where the proteins were located in zebrafish embryos. They found, broadly, two categories; those in which both protein partners are present in the same tissue (and likely to be involved in cell adhesion) and those in which they are present in adjoining tissues (and therefore likely to be involved in communication between tissues). Half of the proteins interact with more than one other protein, forming interaction networks.

The results provide the first network of low-affinity interactions between proteins on the cell surface and the first set of extensive data in the zebrafish, a leading organism for following visually the effects of gene disruption.

"AVEXIS is not restricted to only one specific organism and could be used in many contexts," explains Dr Wright. "We found in the zebrafish novel interactions for well-studied proteins and can expect that we will be able to similarly enrich our understanding of human protein interactions.

"The novel interactions can lead directly to the study of protein distribution patterns and to candidates for drug targeting. If an interaction lacks one component that underlies a disease, then one can seek to find small molecules or antibodies that will act to stimulate the network at the point where the absent or dysfunctional protein would be active."

The Sanger Institute team are interested in using this method to identify the proteins on our cells to which pathogens attach: the contact between pathogen proteins and their host cell surface receptors is often the initiating event during infections. Because extracellular proteins are readily accessible to drugs delivered through the bloodstream, AVEXIS should help to identify novel therapeutic opportunities in both genetic and infectious diseases.


'/>"/>

Contact: Don Powell
don@sanger.ac.uk
44-012-234-96928
Wellcome Trust Sanger Institute
Source:Eurekalert

Related medicine news :

1. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
2. Novel virus detection identifies new viruses in study of respiratory infections and asthma attacks
3. Researchers uncover novel mechanism that balances the sizes of functional areas in the brain
4. Novel Cooling Therapy May Have Aided Injured Football Player
5. ECLIPSE data on effects of Otsukas investigational novel treatment, Tolvaptan
6. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
7. GrantAdler Shipping Novel Implantable Vascular Access Port
8. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
9. Novel strategy under study for aggressive leukemia
10. ISTO Technologies Receives 510(k) Clearance for a Novel Bone Graft Substitute and Bone Graft Extender
11. 454 Sequencing(TM): Science Paper Describes a Novel, Highly Efficient Method of Sequencing Ancient DNA; Sequences the Mitochondria of 10 Individual Mammoths to Prove It
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/26/2016)... , ... June 27, 2016 , ... Quality metrics are ... in many ways they remain in the eye of the beholder, according to experts ... publication of The American Journal of Managed Care. For the full issue, click ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
Breaking Medicine Technology: